Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer
Phase 3
Recruiting
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000001537
- Lead Sponsor
- Wakayama Medical University, Department of Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with other cancer requiring treatment 2. Patients with serious complications 3. Patients who fall under the following(Leukocyte count < 3,000/uL, Hemoglobin < 10.0g/dL, Platelet count < 75,000/uL, AST, ALT and ALP > 2.5 times upper limit of normal (ULN), Serum Creatinine > 1.5 times ULN)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biochemical progression-free survival (PFS)
- Secondary Outcome Measures
Name Time Method Overall survival Cause- specific survival Clinical progression-free survival QOL Safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie androgen deprivation therapy synergy with HDR brachytherapy in locally advanced prostate cancer?
How does combined androgen deprivation plus HDR brachytherapy compare to standard EBRT in Phase III trials for prostate cancer outcomes?
Which biomarkers correlate with improved survival in JPRN-UMIN000001537's combined ADT and HDR brachytherapy regimen?
What are the long-term adverse event profiles of HDR brachytherapy combined with androgen deprivation in prostate cancer patients?
What combination therapies are being explored alongside HDR brachytherapy for locally advanced prostate cancer in Wakayama Medical University trials?